SCHILKE TOBIN (CFO) received a stock award from REVANCE THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 1/3/2024ACC: 0001479290-24-000005
Officer· CFO
Since Nov 2018
+434.00
Net shares
Net buyer
$3.2K
Total acquired
0
Open market trades
0B · 0S
1
Total transactions
434.00 acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+434.00
Price / share
$7.47
Trade value
$3.24K
% of position
0.5%
12/31/2023
91.30K→91.73K
Total
Net shares
+434.00
Net value
$3.24K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/31/2023 | A · Award | +434.00 | $7.47 | $3.24K | 0.5% | 91.30K | 91.73K |
| Total | +434.00 | $3.24K | ||||||
Derivative Transactions0
No derivative transactions reported